Welcome to our Business Page!
One of my key goals as Ambassador is to increase trade and business activities between Tunisia and the United States. As a part of President Obama’s National Export Initiative (NEI) that seeks to double U.S. exports by 2015, this Embassy is working energetically to promote business-to-business relations and advocate for U.S. companies in order to actively expand trade and investment opportunities for U.S. companies in Tunisia.
As Ambassador, I have been fortunate to work with many U.S. companies doing or seeking to do business in Tunisia, and I have met with many Tunisian companies trying to improve their business prospects in the United States. I have actively encouraged government, business and civil society leaders in Tunisia to promote a secure, investment-friendly environment to allow us to expand and strengthen the economic ties between our two great countries. We use every opportunity, including meetings at the Embassy, trade shows, and networking and promotional events, to showcase products, discuss policies, or simply bring the right people together. There are numerous success stories to report and I hope to see many more.
The U.S. Embassy is dedicated to promoting and protecting U.S. commercial interests in Tunisia, and stands ready to offer a variety of services to both American and Tunisian companies. I hope you find the information on this site useful, and please do call upon us to assist you in whatever way we can.
REQUEST FOR PROPOSAL: U.S. Army Contract Solicitation for Drug Manufacturing & Testing
The U.S. Army Medical Material Development Activity (USAMMDA) develops new drugs, vaccines, and medical support equipment that enhance readiness, ensures the provision of the highest quality medical care to the DoD, and maximizes survival of medical casualties on the battlefield. USAMMDA Pharmaceutical Systems Project Management Office has a requirement to provide product manufacturing and testing of two topical antileishmanial drugs, currently in Phase 3 clinical trials and nearing filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).
The base requirement is to manufacture and test 4 lots of WR 279,396 and Paromomycin Alone cream (2 lots each) using the Batch Production Record and testing procedure to be provided by the Government. The contract will encompass WR 279,396 (15% paromomycin and 0.5% gentamicin in a hydrophilic cream base) and Paromomycin Alone cream (15% paromomycin in the same hydrophilic cream base). Further details of the requirement can be found in the contract solicitation, located here:
All questions and requests for additional information are due by 20 March 2013, and should be forwarded to the Contracting Officer (firstname.lastname@example.org) or Contract Specialist (Kelly.email@example.com).
- Greater New York Dental Meeting 2013 (November 29–December 4, 2013)
- SIAMAP 2013, Tunis, Tunisia (November 27- December 1, 2013)
- SFAX Business Fair (November 20-21, 2013)
- Global Entrepreneurship Week (GEW) in Tunisia (Nov. 18-24, 2013)
- POWER-GEN® International 2013 (November 12–14, 2013)
- American Film Market 2013 (November 6–13, 2013)
JOIN THE BILATERAL TRADE DISCUSSION
Tunisia and the United States signed a Trade Investment Framework Agreement (TIFA) in 2002, and in October 2011, talks were relaunched to deepen engagement via this agreement. We welcome input from the private sector on which issues we should address. If you have thoughts, please send them to us at TunisCommercial@state.gov.
Bilateral Agreements and Statements:
President’s Investment Framework
Joint Statement on the U.S. –Tunisia Joint Political and Economic Partnership (JPEP)
Trade and Investment Framework Agreement (TIFA)
Bilateral Investment Treaty (BIT)
Non-Double Taxation Treaty
Facts and Figures
Bilateral Trade Statistics
Select USA Monthly Update (PDF 81.20 KB)